Cardiac Biomarkers Market Set to Reach USD 28 Billion by 2030, Driven by Rising Incidence of Cardiovascular Diseases

Cardiac Biomarkers Market Set to Reach USD 28 Billion by 2030, Driven by Rising Incidence of Cardiovascular Diseases

 

According to Next Move Strategy Consulting, the global Cardiac Biomarkers Market is projected to grow to USD 28 billion by 2030, representing a robust Compound Annual Growth Rate (CAGR) of 12% during the forecast period by 2030. This growth is driven by the increasing prevalence of cardiovascular diseases (CVDs), technological advancements in diagnostic tools, and the rising adoption of cost-effective and accurate Point of Care (PoC) testing kits for heart-related conditions.

Download Free Sample: https://www.nextmsc.com/cardiac-biomarkers-market/request-sample

Market Overview

Cardiac biomarkers are protein-based substances that are released into the bloodstream when the heart experiences extreme stress or damage. These biomarkers are essential for diagnosing cardiovascular diseases such as Acute Coronary Syndrome (ACS), myocardial infarction, and cardiac ischemia, among others. By enabling rapid and precise diagnostics, cardiac biomarkers play a crucial role in the early detection, monitoring, and prevention of CVDs, facilitating timely interventions.

Due to the high sensitivity of cardiac biomarkers, tests can produce quick and reliable results, which are pivotal in managing heart conditions. The rise in demand for affordable PoC testing kits, which deliver faster results with higher accuracy, has significantly contributed to the growth of the cardiac biomarkers market.

Market Dynamics and Trends

The World Health Organization (WHO) reports that more than 17.9 million people die from cardiovascular diseases each year. This alarming statistic is propelling the demand for advanced diagnostic and treatment solutions. As the global healthcare infrastructure continues to evolve, the need for precise and efficient diagnostics, such as cardiac biomarkers, has become more critical than ever.

Key benefits of cardiac biomarkers include their ability to provide fast and accurate assessments of heart failures, particularly in emergency scenarios like chest pain. Furthermore, their high sensitivity ensures accurate results, making them indispensable in clinical settings. However, the limited use of biomarkers in certain cases and potential risks associated with skeletal injury remain challenges to market growth.

Despite these limitations, the development of customized biomarker testing solutions and increasing investment in research and development (R&D) are expected to accelerate market growth in the coming years. Additionally, the availability of diverse cardiac biomarker combinations and the growing number of new clinical research initiatives will further fuel market expansion.

Inquire Before Buying: https://www.nextmsc.com/cardiac-biomarkers-market/inquire-before-buying

Market Segmentation

The global cardiac biomarkers market has been segmented based on product type, application, testing location, and geography:

  • By Product Type: Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs), Ischemia Modified Albumin (IMA), and others.
  • By Application: Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and others.
  • By Location of Testing: Point of Care Testing and Laboratory Testing.

Geographical Insights

North America currently leads the global cardiac biomarkers market, owing to its advanced healthcare infrastructure, high adoption of PoC testing, and rising incidence of CVDs. The region is expected to maintain its dominance throughout the forecast period.

In contrast, the Asia-Pacific region is poised for significant growth, driven by increased access to healthcare, a high burden of CVDs due to rapidly growing populations, and a surge in medical tourism. This region is also seeing rising awareness about the importance of early detection and treatment of heart diseases.

Competitive Landscape

The cardiac biomarkers market is highly competitive, with key players including Roche Diagnostics, Siemens Healthcare, Abbott Laboratories, Alere Inc., Bio-Rad Laboratories, Becton Dickinson and Company, BioMerieux, Beckman Coulter, Randox Laboratories, and Thermo Fisher Scientific. These companies are increasingly investing in R&D to develop innovative products and solutions to meet the growing demand for efficient cardiac diagnostics.

For example, in September 2019, Abbott introduced a breakthrough product—its High Sensitivity Troponin-I (hsTnI) blood test, which allows doctors to assess heart attack risk within hours of patient admission. This test has already received approval for commercialization in the U.S. and is expected to play a significant role in diagnosing heart attacks more effectively in both men and women.

Conclusion

The global cardiac biomarkers market is poised for substantial growth, driven by the rising incidence of cardiovascular diseases, technological advancements in diagnostic tools, and the increasing demand for rapid, accurate, and cost-effective diagnostic solutions. The adoption of PoC testing kits, along with strong investments in R&D, will continue to shape the market landscape and open up new opportunities for stakeholders in the coming years.

Also, Browse Related Reports:    

For more information, please contact:

Next Move Strategy Consulting

E-Mail: info@nextmsc.com

Direct: +1-217-650-7991

Website: www.nextmsc.com

Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

Back to blog